Download PDFPDF
Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re: Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine
    • Julia G Costantini, Medical Student Case Western Reserve University School of Medicine
    • Other Contributors:
      • Thomas L Steinemann, Professor of Ophthalmology, Case Western Reserve University School of Medicine
      • Bruce H Koffler, Associate Clinical Professor of Ophthalmology, University of Kentucky School of Medicine

    Dear Editor,

    Corneal graft rejection following vaccination was first reported in 1988 by T L Steinemann, B H Koffler and C D Jennings [1]. This article is missing from Table 1, “Summary of reported cases of corneal graft rejection”. As it is the first published study to describe this temporal association, it merits mention.

    In regards to preventative measures, we recommend thoroughly counseling patients with grafts. They should be educated on the salient warning signs of rejection including pain, redness, blurred vision, and irritation. Patients should also be informed that COVID-19 vaccination may pose a risk to the viability of their corneal grafts. We recommend prophylactically increasing topical steroids for 3-4 weeks around the time of each vaccination.

    1. Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization. Am J Ophthalmol. 1988 Nov 15;106(5):575-8. doi: 10.1016/0002-9394(88)90588-0. PMID: 3056015.

    Conflict of Interest:
    None declared.